Literature DB >> 14557639

CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 nef protein in pediatric AIDS progression.

Nicoletta Casartelli1, Gigliola Di Matteo, Marina Potestà, Paolo Rossi, Margherita Doria.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) nef gene is a crucial determinant in AIDS disease progression. Although several in vitro activities have been attributed to the Nef protein, identifying the one critical for in vivo pathogenicity remains elusive. In this study, we examined a large number of nef alleles derived at various time points from 13 perinatally infected children showing different progression rates: six nonprogressors (NPs), three slow progressors (SPs), and four rapid progressors (RPs). The patient-derived nef alleles were analyzed for their steady-state expression of a Nef protein, for their relative ability to downregulate cell surface expression of CD4 and major histocompatibility complex class I (MHC-I) and for their capacity to bind the clathrin adaptor AP-1 complex. We found that NP-derived nef alleles, compared to nef alleles isolated from SPs and RPs, had reduced CD4 and MHC-I downregulation activities. In contrast, SP- and RP-derived nef alleles did not differ and efficiently downregulated both CD4 and MHC-I. AP-1 binding was a conserved function of primary nef alleles not correlated with clinical progression. Defective Nef proteins from NPs, rather than sharing common specific changes in their sequences, accumulated various amino acid substitutions, mainly located outside the conserved domains previously associated with Nef biological properties. Our data indicate that Nef-mediated downregulation of cell surface CD4 and MHC-I significantly contributes to the expression of the pathogenic potential of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557639      PMCID: PMC229262          DOI: 10.1128/jvi.77.21.11536-11545.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes.

Authors:  V Piguet; L Wan; C Borel; A Mangasarian; N Demaurex; G Thomas; D Trono
Journal:  Nat Cell Biol       Date:  2000-03       Impact factor: 28.824

Review 2.  Structure--function relationships in HIV-1 Nef.

Authors:  M Geyer; O T Fackler; B M Peterlin
Journal:  EMBO Rep       Date:  2001-07       Impact factor: 8.807

3.  Disrupting surfaces of nef required for downregulation of CD4 and for enhancement of virion infectivity attenuates simian immunodeficiency virus replication in vivo.

Authors:  A J Iafrate; S Carl; S Bronson; C Stahl-Hennig; T Swigut; J Skowronski; F Kirchhoff
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Simian and human immunodeficiency virus Nef proteins use different surfaces to downregulate class I major histocompatibility complex antigen expression.

Authors:  T Swigut; A J Iafrate; J Muench; F Kirchhoff; J Skowronski
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Sequence heterogeneity of Nef transcripts in HIV-1-infected subjects at different stages of disease.

Authors:  L Ratner; T Joseph; J Bandres; S Ghosh; N Vander Heyden; A Templeton; B Hahn; W Powderly; M Arens
Journal:  Virology       Date:  1996-09-01       Impact factor: 3.616

6.  Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS.

Authors:  S Carl; T C Greenough; M Krumbiegel; M Greenberg; J Skowronski; J L Sullivan; F Kirchhoff
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Functional and structural defects in HIV type 1 nef genes derived from pediatric long-term survivors.

Authors:  R Geffin; D Wolf; R Müller; M D Hill; E Stellwag; M Freitag; G Sass; G B Scott; A S Baur
Journal:  AIDS Res Hum Retroviruses       Date:  2000-11-20       Impact factor: 2.205

8.  Efficient class I major histocompatibility complex down-regulation by simian immunodeficiency virus Nef is associated with a strong selective advantage in infected rhesus macaques.

Authors:  J Münch; N Stolte; D Fuchs; C Stahl-Hennig; F Kirchhoff
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Association between HIV-specific T helper responses and CTL activities in pediatric AIDS.

Authors:  T J Wasik; A Wierzbicki; V E Whiteman; G Trinchieri; H W Lischner; D Kozbor
Journal:  Eur J Immunol       Date:  2000-01       Impact factor: 5.532

10.  Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes.

Authors:  Christopher A Lundquist; Minoru Tobiume; Jing Zhou; Derya Unutmaz; Christopher Aiken
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

View more
  14 in total

1.  The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.

Authors:  Giulia Matusali; Marina Potestà; Angela Santoni; Cristina Cerboni; Margherita Doria
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable.

Authors:  Kristin Agopian; Bangdong L Wei; J Victor Garcia; Dana Gabuzda
Journal:  Virology       Date:  2006-09-18       Impact factor: 3.616

3.  Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation.

Authors:  Andrea Crotti; Francesca Neri; Davide Corti; Silvia Ghezzi; Silvia Heltai; Andreas Baur; Guido Poli; Elena Santagostino; Elisa Vicenzi
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

4.  Primary human immunodeficiency virus type 1 nef alleles show major differences in pathogenicity in transgenic mice.

Authors:  Elena Priceputu; Zaher Hanna; Chunyan Hu; Marie-Chantal Simard; Patrick Vincent; Steffen Wildum; Michael Schindler; Frank Kirchhoff; Paul Jolicoeur
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

5.  An Amino Acid Polymorphism within the HIV-1 Nef Dileucine Motif Functionally Uncouples Cell Surface CD4 and SERINC5 Downregulation.

Authors:  Mitchell J Mumby; Aaron L Johnson; Steven M Trothen; Cassandra R Edgar; Richard Gibson; Peter B Stathopulos; Eric J Arts; Jimmy D Dikeakos
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

Review 6.  HIV-1 gp120 binding to dendritic cell receptors mobilize the virus to the lymph nodes, but the induced IL-4 synthesis by FcepsilonRI+ hematopoietic cells damages the adaptive immunity--a review, hypothesis, and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2004-08       Impact factor: 2.198

7.  Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo.

Authors:  Daniele Accapezzato; Vincenzo Visco; Vittorio Francavilla; Caroline Molette; Tiziana Donato; Marino Paroli; Mario U Mondelli; Margherita Doria; Maria Rosaria Torrisi; Vincenzo Barnaba
Journal:  J Exp Med       Date:  2005-09-12       Impact factor: 14.307

8.  Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1 stimulates viral infection.

Authors:  Margherita Doria; Francesca Neri; Angela Gallo; Maria Giulia Farace; Alessandro Michienzi
Journal:  Nucleic Acids Res       Date:  2009-08-03       Impact factor: 16.971

9.  Attenuation of multiple Nef functions in HIV-1 elite controllers.

Authors:  Philip Mwimanzi; Tristan J Markle; Eric Martin; Yoko Ogata; Xiaomei T Kuang; Michiyo Tokunaga; Macdonald Mahiti; Florencia Pereyra; Toshiyuki Miura; Bruce D Walker; Zabrina L Brumme; Mark A Brockman; Takamasa Ueno
Journal:  Retrovirology       Date:  2013-01-07       Impact factor: 4.602

10.  HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells.

Authors:  Malinda R Schaefer; Elizabeth R Wonderlich; Jeremiah F Roeth; Jolie A Leonard; Kathleen L Collins
Journal:  PLoS Pathog       Date:  2008-08-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.